Published by Josh White on 29th May 2025
(Sharecast News) - Sareum announced the start of a programme of toxicology studies on Thursday, for its lead TYK2/JAK1 inhibitor - SDC-1801 - marking a key step toward phase two clinical development.
URL: http://www.digitallook.com/dl/news/story/35114180/...